Switch theme
Sign up to access all valuation multiples
Curasight AS is a clinical-stage biotech company committed to improving both the diagnosis and the treatment of certain types of cancer. The company is focused on generating data with both uTRACE and uTREATÂ in cancers, including prostate cancer and glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer.
2013
4
Last FY Revenue n/a
LTM EBITDA -$7.1M
$17.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Curasight has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$7.1M.
In the most recent fiscal year, Curasight achieved revenue of n/a and an EBITDA of -$6.2M.
Curasight expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Curasight valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$5.2M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$7.1M | XXX | -$6.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$7.1M | XXX | -$6.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$6.5M | XXX | -$5.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Curasight's stock price is DKK 2 (or $0).
Curasight has current market cap of DKK 111M (or $17.4M), and EV of DKK 109M (or $17.2M).
See Curasight trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.2M | $17.4M | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Curasight has market cap of $17.4M and EV of $17.2M.
Curasight's trades at n/a EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate Curasight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curasight has a P/E ratio of -2.7x.
See valuation multiples for Curasight and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.4M | XXX | $17.4M | XXX | XXX | XXX |
| EV (current) | $17.2M | XXX | $17.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -2.4x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -3.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCurasight's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.3M for the same period.
Curasight's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Curasight's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Curasight and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curasight acquired XXX companies to date.
Last acquisition by Curasight was XXXXXXXX, XXXXX XXXXX XXXXXX . Curasight acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Curasight founded? | Curasight was founded in 2013. |
| Where is Curasight headquartered? | Curasight is headquartered in Sweden. |
| How many employees does Curasight have? | As of today, Curasight has 4 employees. |
| Is Curasight publicy listed? | Yes, Curasight is a public company listed on SAT. |
| What is the stock symbol of Curasight? | Curasight trades under CURAS ticker. |
| When did Curasight go public? | Curasight went public in 2020. |
| Who are competitors of Curasight? | Similar companies to Curasight include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Curasight? | Curasight's current market cap is $17.4M |
| Is Curasight profitable? | Yes, Curasight is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Curasight? | Curasight's last 12 months EBITDA is -$7.1M. |
| What is the current EV/EBITDA multiple of Curasight? | Current EBITDA multiple of Curasight is -2.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
